Successful hematopoietic stem cell transplantation from an HLA-mismatched parent for engraftment failure after unrelated cord blood transplantation in patients with juvenile myelomonocytic leukemia: Report of two cases.
Child, Preschool
Cord Blood Stem Cell Transplantation
/ methods
Female
Fetal Blood
HLA Antigens
/ immunology
Hematopoietic Stem Cell Transplantation
/ methods
Hematopoietic Stem Cells
/ cytology
Hepatomegaly
/ surgery
Humans
Immunosuppressive Agents
/ therapeutic use
Infant
Leukemia, Myelomonocytic, Juvenile
/ therapy
Male
Mutation
Recurrence
Splenomegaly
/ surgery
Transplantation Conditioning
Treatment Outcome
CBT
GVHD
HLA-mismatched parent
JMML
RIC
engraftment failure
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
06
06
2018
revised:
08
08
2018
accepted:
21
01
2019
pubmed:
21
2
2019
medline:
26
3
2020
entrez:
21
2
2019
Statut:
ppublish
Résumé
JMML is an aggressive hematopoietic malignancy of early childhood, and allogeneic HSCT is the only curative treatment for this disease. Umbilical cord blood is one of donor sources for HSCT in JMML patients who do not have an HLA-compatible relative, but engraftment failure remains a major problem. Here, we report two cases of JMML who were successfully rescued by HSCT from an HLA-mismatched parent after development of primary engraftment failure following unrelated CBT. Both patients had severe splenomegaly and underwent unrelated CBT from an HLA-mismatched donor. Immediately after diagnosis of engraftment failure, both patients underwent HSCT from their parent. For the second HSCT, we used RIC regimens consisting of FLU, CY, and a low dose of rabbit ATG with or without TBI and additionally administered ETP considering their persistent severe splenomegaly. Both patients achieved engraftment without severe treatment-related adverse effects. After engraftment of second HSCT, their splenomegaly was rapidly regressed, and both patients showed no sign of relapse for over 4 years. These observations demonstrate that HSCT from an HLA-mismatched parent could be a feasible salvage treatment for primary engraftment failure in JMML patients.
Substances chimiques
HLA Antigens
0
Immunosuppressive Agents
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13378Informations de copyright
© 2019 Wiley Periodicals, Inc.